{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:31:56Z","timestamp":1790188316307,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-89525-9","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T13:27:24Z","timestamp":1739885244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of upper tract urothelial carcinoma history on patients with non-muscle invasive bladder cancer undergoing intravesical chemotherapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Jiaxiang","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Hui","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haopu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"issue":"8","key":"89525_CR1","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters, A., Aben, K. K. H. & Kiemeney, L. The global burden of urinary bladder cancer: an update. World J. Urol. 38(8), 1895\u20131904 (2020).","journal-title":"World J. Urol."},{"key":"89525_CR2","doi-asserted-by":"crossref","unstructured":"Kamat, A. M. et al. Bladder cancer Lancet 388(10061), 2796\u20132810 (2016).","DOI":"10.1016\/S0140-6736(16)30512-8"},{"issue":"3","key":"89525_CR3","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","volume":"49","author":"RJ Sylvester","year":"2006","unstructured":"Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49(3), 466\u2013465 (2006). discussion 75\u2009\u2013\u20097.","journal-title":"Eur. Urol."},{"issue":"2","key":"89525_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s00345-015-1598-0","volume":"34","author":"RJ Lammers","year":"2016","unstructured":"Lammers, R. J. et al. Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. World J. Urol. 34(2), 173\u2013180 (2016).","journal-title":"World J. Urol."},{"issue":"5","key":"89525_CR5","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","volume":"182","author":"J Fernandez-Gomez","year":"2009","unstructured":"Fernandez-Gomez, J. et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J. Urol. 182(5), 2195\u20132203 (2009).","journal-title":"J. Urol."},{"issue":"1","key":"89525_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","volume":"69","author":"S Cambier","year":"2016","unstructured":"Cambier, S. et al. EORTC nomograms and Risk groups for Predicting recurrence, progression, and Disease-specific and overall survival in Non-muscle-invasive Stage Ta-T1 urothelial bladder Cancer patients treated with 1\u20133 years of maintenance Bacillus Calmette-Guerin. Eur. Urol. 69(1), 60\u201369 (2016).","journal-title":"Eur. Urol."},{"issue":"1","key":"89525_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat, M. et al. European Association of Urology Guidelines on Upper urinary tract Urothelial Carcinoma: 2023 update. Eur. Urol. 84(1), 49\u201364 (2023).","journal-title":"Eur. Urol."},{"issue":"2","key":"89525_CR8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.urolonc.2009.06.003","volume":"29","author":"MD Az\u00e9mar","year":"2011","unstructured":"Az\u00e9mar, M. D., Comperat, E., Richard, F., Cussenot, O. & Roupr\u00eat, M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol. Oncol. 29(2), 130\u2013136 (2011).","journal-title":"Urol. Oncol."},{"issue":"1","key":"89525_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.urolonc.2021.09.022","volume":"40","author":"M Harvey","year":"2022","unstructured":"Harvey, M. et al. Critical shortage in BCG immunotherapy: how did we get here and where will it take us? Urol. Oncol. 40(1), 1\u20133 (2022).","journal-title":"Urol. Oncol."},{"issue":"3","key":"89525_CR10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/S0022-5347(17)37316-0","volume":"147","author":"DL Lamm","year":"1992","unstructured":"Lamm, D. L. et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol. 147(3), 596\u2013600 (1992).","journal-title":"J. Urol."},{"issue":"6","key":"89525_CR11","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1111\/bju.14793","volume":"124","author":"ES Larsen","year":"2019","unstructured":"Larsen, E. S., Nordholm, A. C., Lillebaek, T., Holden, I. K. & Johansen, I. S. The epidemiology of Bacille Calmette-Guerin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 124(6), 910\u2013916 (2019).","journal-title":"BJU Int."},{"issue":"5","key":"89525_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1038\/s41585-022-00578-1","volume":"19","author":"JY Teoh","year":"2022","unstructured":"Teoh, J. Y. et al. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat. Rev. Urol. 19(5), 280\u2013294 (2022).","journal-title":"Nat. Rev. Urol."},{"issue":"11","key":"89525_CR13","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/jjco\/hyt129","volume":"43","author":"A Ito","year":"2013","unstructured":"Ito, A. et al. Intravesical seeding of upper urinary tract urothelial carcinoma cells during nephroureterectomy: an exploratory analysis from the THPMG trial. Jpn J. Clin. Oncol. 43(11), 1139\u20131144 (2013).","journal-title":"Jpn J. Clin. Oncol."},{"issue":"8","key":"89525_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1442-2042.2005.01155.x","volume":"12","author":"T Habuchi","year":"2005","unstructured":"Habuchi, T. Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications. Int. J. Urol. 12(8), 709\u2013716 (2005).","journal-title":"Int. J. Urol."},{"issue":"6","key":"89525_CR15","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.urolonc.2020.01.008","volume":"38","author":"T van Doeveren","year":"2020","unstructured":"van Doeveren, T. et al. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: are they clonally related? A systematic review. Urol. Oncol. 38(6), 590\u2013598 (2020).","journal-title":"Urol. Oncol."},{"issue":"5","key":"89525_CR16","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/bju.15344","volume":"128","author":"KK Bree","year":"2021","unstructured":"Bree, K. K. et al. Impact of upper tract urothelial carcinoma on response to BCG in patients with non-muscle-invasive bladder cancer. BJU Int. 128(5), 568\u2013574 (2021).","journal-title":"BJU Int."},{"issue":"5","key":"89525_CR17","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/bju.14111","volume":"121","author":"M Miyake","year":"2018","unstructured":"Miyake, M. et al. Outcomes of subsequent non-muscle-invasive bladder cancer treated with intravesical Bacillus Calmette-Guerin after radical nephroureterectomy for upper urinary tract urothelial carcinoma. BJU Int. 121(5), 764\u2013773 (2018).","journal-title":"BJU Int."},{"issue":"3","key":"89525_CR18","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/cas.14782","volume":"112","author":"K Shigeta","year":"2021","unstructured":"Shigeta, K. et al. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma. Cancer Sci. 112(3), 1084\u20131094 (2021).","journal-title":"Cancer Sci."},{"key":"89525_CR19","doi-asserted-by":"crossref","unstructured":"Shigeta, K. et al. Profiling the Biological characteristics and transitions through Upper Tract Tumor Origin, bladder recurrence, and muscle-invasive bladder progression in Upper Tract Urothelial Carcinoma. Int. J. Mol. Sci.  23(9) (2022).","DOI":"10.3390\/ijms23095154"},{"issue":"1","key":"89525_CR20","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson, B. D. et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. Nat. Commun. 10(1), 2977 (2019).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89525-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89525-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89525-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:55:21Z","timestamp":1739926521000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-89525-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,18]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["89525"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-89525-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5320315\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,18]]},"assertion":[{"value":"23 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the institutional review board of Peking University People\u2019s Hospital. The data are anonymous, and the requirement of informed consent was therefore waived. However, informed consent from subjects was still obtained from patient whenever possible.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"5977"}}